Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100784 | 0.95 | TGFBR1 (0.35) | TGFBR1ACVR1RIPK2NOD2FYN | |
| SCHEMBL10100600 | 0.84 | EPHX2 (0.43) | TGFBR1ACVR1RIPK2NOD2 | |
| SCHEMBL2357723 | 0.82 | LRRK2 (0.44) | TGFBR1ACVR1RIPK2NOD2 | |
| SCHEMBL10100782 | 0.80 | EPHX2 (0.43) | TGFBR1ACVR1RIPK2NOD2FYN | |
| SCHEMBL10100556 | 0.79 | NEK2 (0.35) | FYNCDK2 | |
| SCHEMBL10100559 | 0.78 | KIT (0.37) | MKNK1ALK | |
| SCHEMBL10100514 | 0.78 | GRIN2B (0.32) | — | |
| SCHEMBL10100575 | 0.78 | KCNN4 (0.33) | — | |
| SCHEMBL10100554 | 0.78 | FYN (0.38) | FYNCDK2 | |
| SCHEMBL10100781 | 0.78 | LRRK2 (0.43) | TGFBR1ACVR1RIPK2NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | TGFBR1 1365/4885ACVR1 576/4885RIPK2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.